Amendments to the Specification

Please replace the paragraph beginning at page 46, line 9 with the following amended paragraph:

Compounds 7 and 9 (which are racemic) were also compared with Casodex in the CWR-22 prostate carcinoma model in nude mice (n=8). All three compounds were administered orally for 14 consecutive days. Both Compounds 7 and 9 exhibited inhibition similar to Casodex (150 mg/kg) when dosed at 75 mpk. The two antipodes of Compound 9 were then separated into Compound ~~25~~ 22 (shown in Table 1) and its mirror image Compound ~~25'~~ 22' (not shown in Table 1). Both compounds were tested *in vivo* in the immature wet prostate weight assay. Compound ~~25~~ 22 showed little activity in the normal tissues while the full antagonist enantiomer Compound ~~25'~~ 22' showed clear activity and a dose response. This is unexpected given the stronger binding affinity and antagonist activity (in MD-453) of Compound ~~25~~ 22. Testing of both compounds in the CWR22 human prostate xenograft model showed the opposite activity profile. Compound ~~25~~ 22 was as potent as Casodex (150 mg/kg) at a 19 mg/kg dose while Compound ~~25'~~ 22' showed no significant activity at the maximum dose tested (75 mpk).